State of Wyoming Takes Position in Halozyme Therapeutics, Inc. $HALO

State of Wyoming bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, Holdings Channel.com reports. The fund bought 6,557 shares of the biopharmaceutical company’s stock, valued at approximately $513,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Empowered Funds LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth about $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC boosted its position in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,448 shares during the period. EverSource Wealth Advisors LLC grew its stake in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 650 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $103.00 on Tuesday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $104.78. The stock’s 50 day moving average is $80.30 and its two-hundred day moving average is $72.79. The firm has a market capitalization of $11.69 billion, a PE ratio of 30.75, a P/E/G ratio of 0.40 and a beta of 0.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HALO shares. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Finally, TD Cowen increased their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,103 shares of company stock valued at $3,142,896 over the last quarter. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.